Rodman & Renshaw initiated coverage on Trevi Therapeutics with a new price target

6/13/24 7:17:44 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Rodman & Renshaw initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $7.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TRVI

Date	Price Target	Rating	Analyst
5/28/2025	$21.00	Buy	H.C. Wainwright
3/10/2025	$9.00 → $29.00	Outperform → Strong Buy	Raymond James
3/10/2025	$8.00 → $25.00	Buy	Needham
12/12/2024	$6.00 → $7.50	Buy	H.C. Wainwright
9/9/2024	$6.00 → $7.00	Outperform	Leerink Partners
8/30/2024	$6.00	Buy	H.C. Wainwright
8/30/2024	$9.00	Outperform	Raymond James
6/13/2024	$7.00	Buy	Rodman & Renshaw